insights_auto
Why is BT3 down 6,90%?
Dive Deeperchevron_right
BT3:FRA
Lineage Cell Therapeutics Inc
€0,78
arrow_downward
-6,90%(-0,058) 1D
2 Okt., 22:00:00 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BT3...
Open
€0,78
High
€0,78
Low
€0,78
Mkt. cap
236,38 m
Avg. vol.
0,00
Volume
0,00
52-wk high
€1,69
52-wk low
€0,78
No. of employees
75
Open
€0,78
High
€0,78
Low
€0,78
Mkt. cap
236,38 m
Avg. vol.
0,00
Volume
0,00
52-wk high
€1,69
52-wk low
€0,78
No. of employees
75
News stories
From web sources and news partners
Simply Wall Street
·
28 minute gelede
Long Lasting Symptom Relief Data Could Be A Game Changer For Vor Biopharma Stock
FXLeaders
·
40 minute gelede
Dow Jones and Nasdaq Futures Open Higher as Buyers Target New Records
Simply Wall Street
·
1 uur gelede
Phase 2 Trial Plans Could Be A Game Changer For Absci Stock (ABSI)
Profile
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
About Lineage Cell Therapeutics Inc